AbbVie: Bipolar Disorder trials

The registry lists 11 Bipolar Disorder studies with AbbVie as lead sponsor. 2 are open to participants now and 6 have results posted.

Phase 1 2Phase 2 6Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar DisorderRecruitingNCT07071532Phase 1
• A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II DisorderRecruitingNCT06696755Phase 2
• Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I DepressionCompletedNCT02670551Phase 3Results posted
• Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I DisorderCompletedNCT02670538Phase 3Results posted
• Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar DepressionCompletedNCT01396447Phase 2Results posted
• Safety and Efficacy of Cariprazine for ManiaCompletedNCT01058096Phase 3Results posted
• Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar DepressionCompletedNCT00852202Phase 2Results posted
• Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute ManiaCompletedNCT00488618Phase 2Results posted
• Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II DisorderCompletedNCT06605599Phase 2
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)CompletedNCT06024239Phase 1
• An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I DisorderCompletedNCT00106405Phase 2